Thursday, August 31, 2017

GlobeImmune Restarts Manufacturing

Louisville, Colorado-based GlobeImmune, the biopharmaceuticals develops which is targeting pancreatic cancer, non-small cell lung cancer (NSCLC), and colerectal cancer, in addition to other cancers, said it has restarted its manufacaturing in Louisville this week. GlobeImmune said the manufacturing will go to support its clinical trials, and comes directly as a result of an acquisition of a controlling interest in the company by NantCell, a California biotechnology developer.